Why Moderna Stock Is Continuing Its Losses Today

The sell-off in Moderna, Inc. MRNA's shares intensified Wednesday amid fears concerning stretched valuation and potential side effects from its mRNA vaccine.

Moderna shares closed at a record high of $484.47 on Monday, propelled by optimism concerning its vaccine against the novel coronavirus. The company last week raised its COVID-19 vaccine delivery forecast for 2021.

On Tuesday, the stock rose to an intra-day high of $497.94 before profit-taking led to a pullback.

Analysts believe the stock — by virtue of its astounding gains notched up since it kickstarted its COVID-19 vaccine program — is pricing in an extremely optimistic forecast for vaccine revenues, as well as a 100% probability of success for the rest of its pipeline.

BofA Securities analyst Geoff Meacham Tuesday said in a note Moderna's valuation has gone from "unreasonable" to "ridiculous."

The stock ended Tuesday's session down 5.73% at $456.76.

The sell-off intensified Wednesday, partly attributable to a release from the European Medicines Agency that said the drug regulator is probing into whether mRNA vaccines from Moderna and Pfizer Inc. PFE/BioNTech SA-ADR BNTX are linked with the appearance of three new conditions reported in vaccinated individuals.

The three conditions include erythema multiforme, a form of allergic skin reaction; glomerulonephritis, or kidney inflammation; and nephrotic syndrome, a renal disorder characterized by heavy urinary protein losses.

At last check, Moderna shares were sliding 16.04% to $383.49.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsWIIMHealth CareMoversTrading IdeasGeneralCovid-19COVID-19 VaccinevaccineVaccinesWhy is it moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!